<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368914</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0402, CDR0000491204</org_study_id>
    <secondary_id>R21CA112919</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0402</secondary_id>
    <secondary_id>JHOC-04032602</secondary_id>
    <nct_id>NCT00368914</nct_id>
  </id_info>
  <brief_title>Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>Pharmacodynamic-Guided Dose Finding Study of Rapamycin (Rapamune®, Sirolimus) in Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in&#xD;
      treating patients with metastatic or unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the pharmacodynamic optimal dose of sirolimus, by evaluating p70^s6 kinase&#xD;
           inhibition in peripheral blood mononuclear cells (PBMC) and normal skin, in patients&#xD;
           with metastatic or unresectable solid tumors.&#xD;
&#xD;
        -  Correlate target inhibition in tumor tissue with PBMC and normal skin target inhibition&#xD;
           in patients whose tumors are amenable to sequential tumor biopsies.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Characterize the pharmacokinetics of sirolimus in these patients&#xD;
&#xD;
        -  Determine the pharmacodynamic effects of sirolimus on tumor, normal skin, and normal&#xD;
           oral mucosa of these patients&#xD;
&#xD;
        -  Correlate the pharmacodynamic effects of sirolimus with pharmacokinetics and clinical&#xD;
           effects.&#xD;
&#xD;
        -  Correlate the Akt signaling pathway with pharmacodynamic endpoints.&#xD;
&#xD;
        -  Explore pharmacokinetic-pharmacodynamic and toxicodynamic relationships of sirolimus in&#xD;
           these patients.&#xD;
&#xD;
        -  Quantify the toxicity of sirolimus in these patients.&#xD;
&#xD;
        -  Evaluate, preliminarily, the activity of sirolimus in these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective, dose-escalation study.&#xD;
&#xD;
      Patients receive oral sirolimus once daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sirolimus until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose limiting toxicity. The pharmacodynamic optimal dose is&#xD;
      considered the dose at which 10 patients are treated without requiring further dose&#xD;
      escalation.&#xD;
&#xD;
      Patients undergo blood collection, tumor tissue and normal skin biopsies, and oral mucosal&#xD;
      smears periodically for pharmacodynamic, pharmacokinetic, and biomarker correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic optimal dose of sirolimus by evaluation of p70s6 kinase inhibition in peripheral blood mononuclear cells (PBMC) and normal skin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of target tissue inhibition in tumor tissue with PMBCs and normal skin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of sirolimus on tumor, normal skin, and normal oral mucosa</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pharmacodynamic effects of sirolimus with pharmacokinetics and clinical effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic-pharmacodynamic and toxicodynamic relationships</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of activation of the mTOR pathway in tumor tissue with the antitumor effects of sirolimus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity by NCI Common Toxicity Criteria Version 3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of sirolimus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and progression-free survival by Kaplan-Meier method at 6 and 12 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor malignancy&#xD;
&#xD;
               -  Metastatic or inoperable disease&#xD;
&#xD;
               -  Failed curative or standard palliative therapy OR no such therapy exists&#xD;
&#xD;
          -  Evaluable or measurable disease&#xD;
&#xD;
               -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
                  conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Tumor amenable to serial biopsies&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  WBC &gt; 3,500/mm³&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Triglycerides &lt; 2 times ULN&#xD;
&#xD;
          -  Total cholesterol &lt; 2 times ULN&#xD;
&#xD;
          -  Willing to undergo serial tumor biopsies and normal skin biopsies&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No immunodeficiency&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No active infections&#xD;
&#xD;
          -  No other uncontrolled medical conditions that could potentially increase the risk of&#xD;
             toxicities or complications of this therapy&#xD;
&#xD;
          -  No concurrent or second malignancy within the past 5 years&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 12 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade 2&#xD;
&#xD;
               -  Uncontrolled congestive heart failure&#xD;
&#xD;
               -  Uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 170 mm Hg,&#xD;
                  diastolic BP &gt; 95 mm Hg)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior anticancer therapy&#xD;
&#xD;
               -  No unresolved chronic toxicity &gt; CTC grade 2&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  More than 4 weeks since prior surgery except minor procedures (e.g., dental work or&#xD;
             skin biopsy)&#xD;
&#xD;
          -  More than 1 month since prior participation in an investigational drug trial&#xD;
&#xD;
          -  More than 1 month since prior chemotherapy&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Diltiazen&#xD;
&#xD;
               -  Clotrimazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
          -  No concurrent immunosuppressants&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 1;26(25):4172-9. doi: 10.1200/JCO.2008.16.2347.</citation>
    <PMID>18757332</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2010</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

